Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults
HIV Infections

About this trial
This is an interventional prevention trial for HIV Infections focused on measuring HIV Preventive Vaccine, AIDS Vaccines, Adenoviridae
Eligibility Criteria
Inclusion Criteria: Have access to a participating site and are willing to be followed for the duration of the study Willing to receive HIV test results Able to understand and comply with study requirements In good general health Have neutralizing adenovirus antibody levels that are less than a 1:12 ratio Agree to use acceptable methods of contraception for at least 21 days prior to study start and for the duration of the study. Exclusion Criteria: HIV infected Positive hepatitis B surface antigen Positive anti-hepatitis C virus antibodies Prior receipt of an HIV vaccine Immunosuppressive drugs within 168 days prior to first vaccination Have received donated blood within 120 days prior to first vaccination Have received immunoglobulin within 60 days of the first vaccination Live attenuated vaccines or investigational research agents within 30 days prior to first vaccination Subunit or killed vaccines within 14 days prior to first vaccination Current preventive or therapeutic anti-tuberculosis (TB) treatment Any medical, psychiatric, or social condition that would interfere with the study Any occupational or other responsibility that would interfere with the study Serious adverse reactions to vaccines Autoimmune disease Immunodeficiency Active syphilis infection. Participants who have been fully treated for syphilis over 6 months prior to study entry are not excluded. Asthma. Participants who have had completely resolved childhood asthma are not excluded. Diabetes mellitus type I or II. Participants who have had isolated gestational diabetes are not excluded. Thyroid disease or removal of the thyroid Blood vessel swelling within the last 3 years Uncontrolled hypertension Body mass index (BMI) of 40 or higher Bleeding disorder Cancer. Participants whose cancer has been removed and is unlikely to recur during the study are not excluded. Seizure disorder. Participants who have not required medication or had a seizure for 3 years prior to study entry are not excluded. Removal of the spleen or have a nonfunctioning spleen Psychiatric conditions that may interfere with the study Pregnancy, breastfeeding, or plan to become pregnant during the study
Sites / Locations
- San Francisco Vaccine and Prevention CRS
- Vanderbilt Vaccine CRS
- FHCRC/UW Vaccine CRS